arrow
J

Jean G. Sathish

Bristol-Myers Squibb
H指数:22
被引数:3,978

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies

抗体Fc段工程对转化药理学及安全性的影响:来自工业案例研究的见解

mAbs
IF7.3
2025-07-070
OAAI
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
2024-04-3016
OAAI
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19
2023-07-105
OAAI
Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™
2022-05-2114
OA
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
2021-10-18204
OAAI
Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeys
2018-01-017
PRE
Challenges and approaches for the development of safer immunomodulatory biologics
2013-03-28169
OAAI